Entrada Therapeutics (TRDA) Change in Accured Expenses (2020 - 2026)

Entrada Therapeutics' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$6.0 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 9.03% year-over-year to -$6.0 million; the TTM figure through Mar 2026 stood at $4.2 million (up 445.73% YoY), while the FY2025 annual figure was $4.7 million, up 177.63% from the prior year.
• Change in Accured Expenses was -$6.0 million for Q1 2026 at Entrada Therapeutics, down from $2.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $6.9 million in Q3 2022 to a low of -$6.0 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $357176.5 across 5 years, with a median of $1.6 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses slumped 795.59% in 2023, then jumped 605.88% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at -$4.3 million in 2022, then soared by 145.03% to $2.0 million in 2023, then slumped by 121.74% to -$425000.0 in 2024, then surged by 605.88% to $2.2 million in 2025, then slumped by 376.84% to -$6.0 million in 2026.
• The last three Change in Accured Expenses figures came in at -$6.0 million (Q1 2026), $2.2 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.